Drug intelligence / Profile preview

PB844

Development stage: Preclinical
Lead developer: PEG Biosciences

Overview

PB844 is a naturally occurring biologic being developed by PEG Biosciences for the treatment of neurologic disorders and neurodegenerative diseases. As a candidate in the PEG Biosciences pipeline, it represents a therapeutic approach utilizing naturally derived biological substances to address pathologies within the central nervous system. Specific details regarding its molecular target, mechanism of action, and clinical phase have not been publicly disclosed by the developer, though it is positioned within their portfolio of PEG-enhanced and biological products.

Beyond the preview

Go deeper on PB844.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB844.

Explore the full profile